Contrast-Enhanced 3D Ultrasound Used for Differentiating Focal Liver Lesions
By MedImaging International staff writers
Posted on 14 Jun 2010
A contrast-enhanced (CE) ultrasound (US) appeared as an important modality to show the vascularity in the areas of interest, and it has been used widely in clinical diagnosis of liver lesions. Three-dimensional ultrasonography (3D US) allows three orthogonal planes to spatially demonstrate the features of subjects, which has been frequently used in fetal US. Posted on 14 Jun 2010
Different from the 2D images, CE 3D US acquires the data in a volume of interest (VOI) by automatically scanning with a desired angle and allows reconstruction of tomographic images in three orthogonal planes and renders angiogram-like images. The combination of 3D US and CE US can present the enhancement of lesions in three dimensions and also in parallel slices by multiple-planar visualization. Although many studies on differentiation among various focal liver tumors have been conducted using CE 2D US, and recently a few using CE 2D US with Sonazoid, the exact value of CE 3D US with Sonazoid in the differential diagnosis of various focal liver tumors has not yet been clarified. Sonazoid is manufactured by Nycomed Amersham Imaging (Princeton, NJ, USA).
A research article published in the May 7, 2010, issue of the World Journal of Gastroenterology addresses this question. The researchers, from the Gastroenterological Center, Yokohama City University Medical Center (Japan), retrospectively assessed tumor enhancement patterns, and the diagnostic criteria established using dominant enhancement patterns were then applied to differentiation among focal liver tumors in a prospective study.
In the study, with analysis of the combination of the enhancement in three phases at CE 3D US, the dominant patterns were used as the diagnostic criteria for individual category, and prospective differentiation yielded a good sensitivity, specificity, high Az value, and good to excellent inter-reader agreement, which revealed the potential usage of CE 3D US in differentiating various focal liver lesions. Although there were no significant differences between the prospective diagnosis at CE 3D US and that at CE 2D US, CE 3D US created a spatial and easily understood view for both hemodynamic and morphologic evaluation of focal liver tumors, which were formed only in the physicians' imagination by 2D imaging using complex acquisition methods.
The good to excellent inter-reader agreement in the investigators' previous study about CE 3D US demonstrating characteristic enhancement of hepatocellular carcinomas (HCCs) have indicated, according to the investigators, CE 3D US can exhibit the characteristic enhancement of HCC tumors objectively.
Related Links:
Gastroenterological Center, Yokohama City University Medical Center